Travere Therapeutics, Inc.
TVTX
$28.18
$0.381.37%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 73.41% | 162.11% | 111.49% | 97.54% | 65.98% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 73.41% | 162.11% | 111.49% | 97.54% | 65.98% |
| Cost of Revenue | -6.49% | 0.32% | -9.77% | 1.26% | 0.48% |
| Gross Profit | 581.28% | 1,061.10% | 2,894.11% | 415.85% | 152.81% |
| SG&A Expenses | 46.32% | 31.75% | 17.66% | 13.41% | 9.30% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.87% | 17.66% | 4.90% | 8.04% | 4.87% |
| Operating Income | 45.35% | 144.50% | 81.13% | 42.15% | 28.37% |
| Income Before Tax | 65.09% | 146.89% | 81.69% | 69.66% | 31.84% |
| Income Tax Expenses | 1,379.17% | 109.52% | -76.47% | -79.58% | -205.88% |
| Earnings from Continuing Operations | 63.52% | 146.95% | 81.69% | 69.68% | 31.97% |
| Earnings from Discontinued Operations | 617,775.00% | -- | -- | -- | 100.25% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 104.53% | 146.90% | 81.88% | 69.70% | 33.17% |
| EBIT | 45.35% | 144.50% | 81.13% | 42.15% | 28.37% |
| EBITDA | 69.75% | 190.92% | 102.41% | 53.25% | 35.59% |
| EPS Basic | 104.16% | 140.88% | 84.22% | 73.55% | 38.50% |
| Normalized Basic EPS | 67.10% | 140.97% | 83.90% | 48.86% | 29.70% |
| EPS Diluted | 104.16% | 139.08% | 84.22% | 73.55% | 38.44% |
| Normalized Diluted EPS | 67.10% | 135.62% | 83.90% | 48.86% | 29.70% |
| Average Basic Shares Outstanding | 8.65% | 14.72% | 14.77% | 14.54% | 8.67% |
| Average Diluted Shares Outstanding | 8.65% | 31.94% | 14.77% | 14.54% | 8.67% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |